Trident Texofab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
For the nine months, sales was INR 597.88 million compared to INR 308.49 million a year ago. Revenue was INR 601.83 million compared to INR 311.1 million a year ago. Net income was INR 3.16 million compared to net loss of INR 2.78 million a year ago. Basic earnings per share from continuing operations was INR 0.31 compared to basic loss per share from continuing operations of INR 0.28 a year ago. Diluted earnings per share from continuing operations was INR 0.31 compared to diluted loss per share from continuing operations of INR 0.28 a year ago.